Interestingly, ITGAV and SEZ6L have not previously been identified as early stage ovarian cancer biomarkers, and the levels of both proteins were significantly decreased in sera from women with early stage ovarian cancer compared to healthy controls (Table 2, Figure 3a, bottom panels). This evidence concerns the gene ITGAV and ovarian cancer.